At 6.50 mg/wk — select pack size
Retatrutide is a triple receptor agonist of the GLP-1 / GIP / glucagon system, with the largest body-composition effects reported for any incretin-class peptide in published research.
Retatrutide is an engineered 39-amino-acid peptide that engages three receptors at once: GLP-1 (satiety and insulin), GIP (incretin amplification), and glucagon (hepatic energy expenditure). The triple-action profile is sometimes called a "GGG" tri-agonist.
The design builds on the dual GLP-1/GIP class by adding glucagon receptor activation. Glucagon receptor activation increases hepatic thermogenesis and energy expenditure, something appetite-suppression alone cannot do, which is part of why Retatrutide has produced the largest body-composition shifts seen in this class.
Retatrutide is supplied here as a lyophilised powder for in-vitro and preclinical research only. It is not an approved medicine in any jurisdiction.
Retatrutide simultaneously activates the GLP-1, GIP, and glucagon receptors, combining appetite suppression with direct hepatic energy expenditure for unusually large weight and liver-fat reductions.
| Pathway | Effect | Why it matters |
|---|---|---|
| GLP-1 receptor | Glucose-dependent insulin release, slowed gastric emptying, central satiety | Foundation of the incretin class; reduces hunger and post-meal glucose |
| GIP receptor | Full agonist with 8.9× greater potency than native GIP | Amplifies satiety and improves adipose insulin sensitivity |
| Glucagon receptor | Activates hepatic energy expenditure and thermogenesis | Increases calorie burn and accelerates hepatic fat clearance |
| C20 fatty diacid anchor | Binds serum albumin for long circulation | Extends half-life to ~6 days for once-weekly dosing |
| DPP-IV resistance | Aib2 and Aib20 block protease cleavage | Keeps the peptide intact in circulation |
Jastreboff et al. (NEJM, 2023) published the landmark Phase 2 data: 24.2% mean weight loss at 48 weeks with the 12 mg dose, with more than 90% of participants losing at least 10%. Sanyal et al. (Nature Medicine, 2024) then reported up to 82.4% reduction in liver fat in MASLD trials - a remarkable number for any intervention. The peptide is hepatically metabolised without CYP involvement, so drug-drug interactions are minimal. Steady state is reached in 3-4 weeks of weekly dosing.
Retatrutide is an investigational triple agonist — it activates the GLP-1, GIP and glucagon receptors — developed by Eli Lilly and still in clinical trials (not approved anywhere). Retatrutide is the research-grade form of this retatrutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is not an approved medicine and is not for human use.
In published research retatrutide activates three receptors at once — GLP-1 and GIP (satiety, insulin secretion, adipose effects) plus glucagon (hepatic energy expenditure and liver-fat clearance). The triple mechanism is what distinguishes it from dual (tirzepatide) and single (semaglutide) agonists. These are research findings for the molecule, not human-use guidance; Retatrutide is supplied for research only.
No. Retatrutide is still in clinical trials and is not approved by the FDA, EMA, or any other regulator. Retatrutide is an unapproved, research-grade lyophilised powder supplied for laboratory research use only — not for human consumption.
Retatrutide is investigational; its safety is still being characterised in clinical trials and is not established for general use. Research-grade Retatrutide is not a sterile approved medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.
For laboratory preparation, concentration in mg/mL equals the vial mass in mg divided by the millilitres of diluent added — e.g. a 10 mg vial reconstituted with 1 mL of bacteriostatic water gives 10 mg/mL, or with 2 mL gives 5 mg/mL. Keep the reconstituted vial refrigerated at 1–6 °C and protected from light. This is preparation math only; New-U provides no human-use dosing guidance.
Semaglutide targets one receptor (GLP-1), Tirzepatide targets two (GLP-1 and GIP), and Retatrutide targets three (GLP-1, GIP, and glucagon). The glucagon arm is what drives the additional hepatic thermogenesis and liver-fat clearance that set Retatrutide apart in published research.
It does, but at the right intensity and in combination with GLP-1, glucagon receptor agonism stimulates hepatic energy expenditure and fat oxidation without significant net glucose elevation. The GLP-1 arm offsets any glycemic downside while the glucagon arm delivers unique energy-balance effects.
No. Retatrutide is supplied for in-vitro and preclinical research only and is not approved as a medicine in any jurisdiction.
Published research protocols use a step-up schedule from 1 mg weekly, doubling over several weeks to 2 mg, 4 mg, 8 mg, and ultimately 12 mg. The gradual escalation is designed to minimise GI signals as systems adapt to triple-receptor activation.
Across the published GLP-1 literature, withdrawal of a GLP-1 receptor agonist is consistently followed by the return of appetite and partial-to-substantial regain of lost weight, because the appetite and gastric-emptying effects depend on continued receptor activation. Retatrutide is a triple GIP/GLP-1/glucagon agonist still in clinical trials, so any such observations describe investigational or approved medicines in human studies. Retatrutide is an unapproved research-grade peptide supplied for laboratory research only and is not for human use.
Add the Retatrutide pack size you need to your cart and check out: enter your shipping details, then choose your payment method — cryptocurrency or card — on the next step. Every order ships with its batch Certificate of Analysis (COA). Retatrutide is supplied strictly for laboratory research use only, not for human or veterinary use.
At checkout you can pay by cryptocurrency (BTC, ETH, SOL, LTC, USDC, USDT and more) or by card, each handled by a dedicated secure payment provider. You choose your method after confirming your order.
Yes — we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $300.
| Stability | Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. |
|---|---|
| Notes | Dose-proportional PK; t½ ≈ 6 days; Tmax = 12–72 h; hepatic metabolism without CYP interaction; dose escalation: 1 mg → 2 mg → 4 mg → 8 mg → 12 mg over 20–24 weeks in clinical protocols. Currently in Phase 3 (TRIUMPH program) with 7 readouts expected in 2026. |
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 1–12 mg subcutaneously (dose escalation protocol) | Once weekly subcutaneous injection | – | Dose-proportional PK; t½ ≈ 6 days; Tmax = 12–72 h; hepatic metabolism without CYP interaction; dose escalation: 1 mg → 2 mg → 4 mg → 8 mg → 12 mg over 20–24 weeks in clinical protocols. Currently in Phase 3 (TRIUMPH program) with 7 readouts expected in 2026. |
Published research reports 24.2% mean body-weight reduction at 48 weeks with the 12 mg dose, the largest single-molecule effect in the incretin class.
MASLD trials report up to 82.4% liver fat reduction, the largest hepatic fat effect seen in the GLP-1 family.
HbA1c reductions of 1.3-2.0% in type 2 diabetes with parallel weight loss of up to 16.9%.
Glucagon receptor activation is the first incretin-class mechanism to increase hepatic thermogenesis directly.
Phase 3 TRIUMPH-4 showed concurrent improvement in osteoarthritis pain alongside weight loss.
C20 fatty diacid albumin anchor gives a ~6-day half-life, enabling once-weekly subcutaneous injection.
| Molecular Formula | Complex lipopeptide (C20 diacid conjugate) |
|---|---|
| Molecular Weight | 4894.6 Da |
| Receptors | GLP-1R (EC50 0.775 nM), GIPR (EC50 0.064 nM), GCGR (EC50 5.79 nM) |
| Purity | >99% (HPLC) |
| Form | Lyophilised powder |
| Half-life | ~6 days |
| Route | Subcutaneous injection, once weekly |
| Dose escalation | 1 → 2 → 4 → 8 → 12 mg over 20-24 weeks in clinical trials |
| Storage | Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light. |
Retatrutide represents the third wave of incretin-based metabolic research. First-generation GLP-1 agonists proved the concept. Second-generation dual agonists added GIP. Retatrutide goes one step further by adding glucagon-receptor activation, which uniquely drives hepatic energy expenditure on top of appetite suppression.
The published Phase 2 data (NEJM, 2023) reported 24.2% mean body-weight reduction at 48 weeks, with the curve not yet flattening at study end. Complementary MASLD data (Nature Medicine, 2024) reported up to 82.4% liver-fat reduction, the largest hepatic effect of any incretin-class research compound to date.
New-U Research Compounds supplies Retatrutide as a lyophilised, research-grade powder at >99% HPLC purity, verified by independent third-party labs including Janoshik and Freedom Diagnostics. All material is strictly for in-vitro and preclinical research. Retatrutide is not an approved medicine anywhere in the world, and nothing on this page is medical advice.